奥拉西坦联合鼠神经生长因子治疗重型脑外伤的临床观察及其对血清神经元特异性烯醇化酶的影响
|
摘要
目的:探讨奥拉西坦注射液联合鼠神经生长因子治疗急性重型颅脑损伤的临床效果及其对血清神经元特异性烯醇化酶(neuron-specific enolase NSE)的影响。方法:选择福建中医院大学附属人民医院收治的60例重型颅脑损伤患者,对照组30例给予常规方法治疗14 d。治疗组在对照组常规方法治疗基础上加用奥拉西坦注射液和鼠神经生长因子治疗14 d。观察两组治疗前后格拉斯哥昏迷评分(GCS)、Glasgow(GOS)评分情况以及治疗过程中NSE的变化情况。结果:治疗组治疗第7、14天GCS评分、GOS评分良好率较对照组好,治疗第7天的NSE水平较低,差异有统计学意义(P<0.05)。结论:奥拉西坦注射液联合神经生长因子治疗重型急性颅脑损伤具有较好的临床效果,能够改善预后情况,降低NSE水平,具有一定的临床推广应用价值。
Objective:To investigate the clinical effect of Oxiracetam for injection combined with Mouse Nerve Growth Factor on acute severe craniocerebral injury and its effect on the serum neuron specific enolase(NSE).Method:Sixty patients with severe craniocerebral injury in the Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine were selected,and 30 patients in the control group were treated with normal treatment for 14 days.The treatment group based on conventional treatment were treated with the injection of Oxiracetam and Mouse Nerve Growth Factor for 14 days.The Glasgow Coma Scale(GCS),Glasgow(GOS) score were observed before and after treatment and the change of NSE in the course of treatment was observed in the two groups.Result:The scores of GCS at the seventh and fourteenth day of the treatment and the good rate of GOS in the treatment group were better than the control group,the NSE level at the 7 th day of the treatment group was lower,the differences were statistically significant(P<0.05).Conclusion:Oxiracetam for injection combined with Mouse Nerve Growth Factor in the treatment of severe craniocerebral injury has better clinical efficacy,can improve the prognosis,reduce the level of NSE,which has certain clinical application value.
Objective:To investigate the clinical effect of Oxiracetam for injection combined with Mouse Nerve Growth Factor on acute severe craniocerebral injury and its effect on the serum neuron specific enolase(NSE).Method:Sixty patients with severe craniocerebral injury in the Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine were selected,and 30 patients in the control group were treated with normal treatment for 14 days.The treatment group based on conventional treatment were treated with the injection of Oxiracetam and Mouse Nerve Growth Factor for 14 days.The Glasgow Coma Scale(GCS),Glasgow(GOS) score were observed before and after treatment and the change of NSE in the course of treatment was observed in the two groups.Result:The scores of GCS at the seventh and fourteenth day of the treatment and the good rate of GOS in the treatment group were better than the control group,the NSE level at the 7 th day of the treatment group was lower,the differences were statistically significant(P<0.05).Conclusion:Oxiracetam for injection combined with Mouse Nerve Growth Factor in the treatment of severe craniocerebral injury has better clinical efficacy,can improve the prognosis,reduce the level of NSE,which has certain clinical application value.
引文
[1]李玉艳,梁琳琳,刘晓勇.颅脑损伤患者脑脊液和血清神经元特异性烯醇化酶及髓鞘碱性蛋白水平变化及临床意义[J].国际检验医学杂志,2017,38(10):1338-1340.
[2]李培建,王康,袁晓敏,等.鼠神经生长因子治疗中重度颅脑损伤的有效性和安全性[EB/OL].中华神经创伤外科电子杂志,2016,2(3):132-135.
[3]刘卓,王倩梅,雒番阳,等.奥拉西坦治疗急性重型颅脑损伤合并创伤性休克效果观察[J].解放军医药杂志,2016,28(10):104-107.
[4]吴建伦.奥拉西坦治疗颅脑损伤临床效果观察[J].吉林医学,2014,35(6):1222.
[5]张微微,李小刚,王默力,等.奥拉西坦治疗卒中后认知功能障碍的有效性及安全性[J].中华神经科杂志,2013,46(7):489-493.
[6]罗成义,柯以铨,徐如祥,等.注射用奥拉西坦治疗颅脑损伤的随机、双盲、对照、多中心临床研究[J].中华神经医学杂志,2011,44(2):192-196.
[7]Kim M S,Shutov L P,Gnanasekaran A,et al.Nerve growth factor(NGF)regulates activity of nuclear factor of activated T-cells(NFAT)in neurons via the phosphatidylinositol 3-kinase(PI3K)-Akt-glycogen synthase kinase3β(GSK3β)pathway[J].J Biol Chem,2014,289(45):31349-31360.
[8]吴晓平.神经生长因子对重型颅脑损伤患者血清神经元特异性烯醇化酶和髓鞘碱性蛋白的影响[J].中国药师,2013,16(7):1046-1047.
[9]郑超,乔陈财,唐红军,等.重型颅脑损伤患者血清NSE和MMPs的动态变化及临床意义[J].湖南师范大学学报(医学版),2016,13(4):107-110.
[10]Chiaretti A,Barone G,Riccardi R,et al.NGF,DCX,and NSE upregulation correlates with severity and outcome of head trauma in children[J].Neurology,2009,72(7):609-616.
[11]Zandra Olivecrona,Lars-Owe D Koskinen.The release of S-100B and NSE in severe traumatic head injury is associated with APOEε4[J].Acta Neurochir,2012,154(4):675-680.
[12]李俊,刘红朝,张刚利,等.重型颅脑损伤患者血清NSE检测及其临床意义[J].华中科技大学学报(医学版),2011,40(2):225-228.
[2]李培建,王康,袁晓敏,等.鼠神经生长因子治疗中重度颅脑损伤的有效性和安全性[EB/OL].中华神经创伤外科电子杂志,2016,2(3):132-135.
[3]刘卓,王倩梅,雒番阳,等.奥拉西坦治疗急性重型颅脑损伤合并创伤性休克效果观察[J].解放军医药杂志,2016,28(10):104-107.
[4]吴建伦.奥拉西坦治疗颅脑损伤临床效果观察[J].吉林医学,2014,35(6):1222.
[5]张微微,李小刚,王默力,等.奥拉西坦治疗卒中后认知功能障碍的有效性及安全性[J].中华神经科杂志,2013,46(7):489-493.
[6]罗成义,柯以铨,徐如祥,等.注射用奥拉西坦治疗颅脑损伤的随机、双盲、对照、多中心临床研究[J].中华神经医学杂志,2011,44(2):192-196.
[7]Kim M S,Shutov L P,Gnanasekaran A,et al.Nerve growth factor(NGF)regulates activity of nuclear factor of activated T-cells(NFAT)in neurons via the phosphatidylinositol 3-kinase(PI3K)-Akt-glycogen synthase kinase3β(GSK3β)pathway[J].J Biol Chem,2014,289(45):31349-31360.
[8]吴晓平.神经生长因子对重型颅脑损伤患者血清神经元特异性烯醇化酶和髓鞘碱性蛋白的影响[J].中国药师,2013,16(7):1046-1047.
[9]郑超,乔陈财,唐红军,等.重型颅脑损伤患者血清NSE和MMPs的动态变化及临床意义[J].湖南师范大学学报(医学版),2016,13(4):107-110.
[10]Chiaretti A,Barone G,Riccardi R,et al.NGF,DCX,and NSE upregulation correlates with severity and outcome of head trauma in children[J].Neurology,2009,72(7):609-616.
[11]Zandra Olivecrona,Lars-Owe D Koskinen.The release of S-100B and NSE in severe traumatic head injury is associated with APOEε4[J].Acta Neurochir,2012,154(4):675-680.
[12]李俊,刘红朝,张刚利,等.重型颅脑损伤患者血清NSE检测及其临床意义[J].华中科技大学学报(医学版),2011,40(2):225-228.